CAPTION: German bioscience firm BioNTech reports strong first quarter results. (picture alliance/dpa)
German vaccine developer BioNTech announced strong first quarter turnover and profits on Monday, with both figures significantly up year-on-year.
Net profits rose to €3.7 billion ($3.9 billion) from €1.13 billion in the same months of the previous year. Turnover rose from €2.05 billion in 2021 to €6.37 billion.
BioNTech also confirmed its forecast of a turnover between €13 billion and €17 billion for the current year for its Covid-19 vaccine.
The German bioscience firm and its US partner Pfizer are currently working on further versions of their Covid-19 vaccine against the Omicron variant, and to provide protection against a range of other coronavirus variants, according to the companies.
Data from clinical studies that began in January is "expected in the coming weeks and will be provided to regulators," BioNTech said.
Over the last year, the company made a net profit of €10.3 billion. Turnover reached nearly €19 billion.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
